Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Continuous MTX use lowers risk of CV events in patients with rheumatoid arthritis

17 May 2019

Recent continuous use of methotrexate (MTX) is associated with a 20-percent decrease in cardiovascular events (CVE) in patients with early-onset rheumatoid arthritis (RA), a recent study has shown. In addition, greater MTX use in the first year of cohort entry appears to lower the risk of CVE.

CVE occurred in 3,294 (13.7 percent) patients (28.5 events per 1,000 patient-years; 95 percent CI, 27.6–29.5) over 115,453 patient-years. Multivariate analyses revealed that the model assessing time-varying continuous use in the most recent year produced the best fit.

There was an association between increasing recent MTX and lower CVE risks (hazard ratio [HR] for continuous use vs no use in past 12 months, 0.79; 95 percent CI, 0.70–0.88; p<0.0001). Greater MTX use in the first year after cohort entry also conferred protection against CVE (HR, 0.84; 0.72–0.96; p=0.0048), but this effect decreased with increasing follow-up.

On the other hand, there was no clear association between longer MTX use during the entire follow-up and CVE risk (HR, 0.98; 0.95–1.01; p=0.1441).

This study analysed an inception cohort of 23,994 patients with RA diagnosed after their 65th birthday. Multivariable Cox regression models were fit to examine the associations between time-varying MTX use and time to CVE, controlling for other risk factors.

The investigators used alternative models to assess the cumulative duration of MTX use over the first year, previous year (recent use) and entire duration of follow-up. They also determined whether the strength of the association varied over time.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.